A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

February 27, 2024

Primary Completion Date

July 17, 2025

Study Completion Date

July 17, 2025

Conditions
Prurigo Nodularis
Interventions
DRUG

Ruxolitinib Cream 1.5%

Ruxolitinib Cream 1.5%

Trial Locations (20)

10023

Equity Medical, Llc, New York

19103

Paddington Testing Co Inc, Philadelphia

33147

Advanced Pharma Cr, Llc, Miami

33162

Sullivan Dermatology North Miami Beach Office, North Miami Beach

33615

Olympian Clinical Research, Tampa

37130

International Clinical Research Tennessee Llc, Murfreesboro

42104

Equity Medical, Bowling Green

46250

Dawes Fretzin Clinical Research Group Llc, Indianapolis

48084

Revival Research Institute, Llc Troy, Troy

48326

Oakland Hills Dermatology Pc, Auburn Hills

58103

Red River Research Partners, Fargo

73170

Central Sooner Research, Oklahoma City

75034

North Texas Center For Clinical Research Ntccr, Frisco

78759

Dermresearch, Inc., Austin

83340

St Lukes Clinic Dermatology Ketchum, Ketchum

85008

Saguaro Dermatology, Phoenix

85255

Affiliated Dermatology, Scottsdale

90404

Clinical Science Institute Clinical Research Specialists Inc, Santa Monica

91324

Amicis Research Center Valencia, Northridge

92708

First Oc Dermatology, Fountain Valley

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Incyte Corporation

INDUSTRY